exenatide vs semaglutide for T2DM: Key findings and takeaways from 3 major trials GIPR/GLP-1R dual agonist therapies for

Ying and colleagues demonstrated the mechanism that drives non-oxidative respiration in PC is more defined than oxidative respiration (47)

--- This year brought 26 biosimilars that were approved by the FDA A significant portion of them (16) were denosumab biosimilars: 8 biosimilars referencing Prolia (denosumab for osteoporosis) Additional 8 biosimilars referencing Xgeva (denosumab for cancer-related bone disease) The downstream effects compound: Biosimilars typically reduce costs by 15-35% compared to reference products (this can decrease more as additional biosimilar options become available) Price competition benefits the entire therapeutic category Patients who couldn't afford brand therapy now have accessible options Health systems gain formulary flexibility without compromising clinical outcomes --- The 26 biosimilar approvals in 2025 represent thousands of patients gaining affordable access to proven therapies that may have previously been out of reach

In Japan, the rate stands at 1 in 40,000

Avoid offers that pressure you with limited-window pricing, sellers who refuse to share lot numbers or origins, and any marketplace that ships without coldchain documentation